The AHA Oct. 4 urged the Drug Enforcement Administration and Department of Health and Human Services to extend telehealth flexibilities an additional two years, which would waive the in-person visit requirement prior to the prescribing of controlled substances virtually. The flexibilities were granted during the COVID-19 public health emergency and are set to expire at the end of the year. The AHA urged the DEA to grant the two-year extension and during that time establish a permanent pathway through a special registration process to make the flexibilities permanent, saying that the lack of a permanent rule would "have a profoundly negative impact on the broad range of patients who are reliant on these flexibilities to continue to receive medically necessary prescription medication."

Related News Articles

Headline
Today the Drug Enforcement Administration and Department of Health and Human Services announced that the effective date for the final rule regarding…
Headline
The Department of Health and Human Services and Drug Enforcement Administration published a series of rules Jan. 15 related to telemedicine prescribing of…
Headline
The Department of Health and Human Services Health Sector Cybersecurity Coordination Center Jan. 8 released guidance on cybersecurity for telehealth…
Headline
The Drug Enforcement Administration and Department of Health and Human Services Nov. 15 issued a final rule extending certain telemedicine prescribing…
Headline
In comments Nov. 12 to majority and minority leaders of the House and Senate, the AHA requested that Congress act on key priorities for hospitals and health…
Headline
In this conversation, Johnna Nynas, M.D., obstetrician and gynecologist at Sanford Health Bemidji, discusses the dramatic expansion of maternal telehealth…